This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Endovascular Treatment of Atherosclerotic Lesions in the SFA Using the Sinus-superflex-635 Stent

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2015 by be Medical.
Recruitment status was:  Recruiting
Sponsor:
Information provided by (Responsible Party):
be Medical
ClinicalTrials.gov Identifier:
NCT01816854
First received: March 20, 2013
Last updated: July 15, 2015
Last verified: July 2015
  Purpose
In this prospective study, a newly developed self-expanding nitinol stent is evaluated for the treatment of atherosclerotic lesions in the superficial femoral artery.

Condition Intervention
Atherosclerotic Heart Disease Device: Stenting

Study Type: Observational [Patient Registry]
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Target Follow-Up Duration: 12 Months
Official Title: Endovascular Treatment of Atherosclerotic Lesions in the SFA Using the Sinus-superflex-635 Stent

Further study details as provided by be Medical:

Primary Outcome Measures:
  • Binary restenosis [ Time Frame: 12 months ]
    Binary restenosis is defined as a re-obstruction ≥ 50% of the target lesion (peak systolic velocity ratio > 2.4).


Secondary Outcome Measures:
  • Immediate procedural outcome (procedural, technical and device success) [ Time Frame: peri-procedural ]

    Procedural success: combination of technical success, device success and absence of procedural complications.

    Technical success: successful vascular access and completion of the endovascular procedure and immediate morphological success with less than 30% residual diameter reduction of the treated lesion on completion angiography.

    Device success: exact deployment of the device according to the instructions for use as documented with suitable imaging modalities and in case of digital substraction angiography, in at least two different imaging projections.


  • Distribution of Rutherford stages [ Time Frame: 12 months ]
  • Primary sustained clinical improvement [ Time Frame: 12 months ]
    Defined as sustained upward shift of at least one category on the Rutherford classification without the need for repeated target lesion revascularization (TLR) in surviving patients.

  • Secondary sustained clinical improvement at 12 months [ Time Frame: 12 months ]
    Defined as sustained upward shift of at least one category on the Rutherford classification including the need for repeated TLR in surviving patients.

  • Mortality [ Time Frame: 30-day mortality ]
    post-procedural

  • Mortality [ Time Frame: 12 months ]
  • Repeated target lesion revascularization (TLR) rate [ Time Frame: 12 months ]
  • Repeated target extremity revascularization (TER) rate [ Time Frame: 12 months ]
  • Amputation rate [ Time Frame: 12 months ]
  • Rate of patient clopidogrel resistance [ Time Frame: 1 month ]

Estimated Enrollment: 300
Study Start Date: January 2013
Estimated Study Completion Date: January 2016
Estimated Primary Completion Date: January 2016 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Patients with PAD Device: Stenting

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients who suffer from intermittent claudication and critical limb ischemia (TASC A, B and C lesions).
Criteria

Inclusion Criteria:

  • Patient must sign informed consent prior to the index-procedure
  • Patient must be older than 18 years
  • Patient must be compliant with follow-up dates at 1 month and 12 months
  • Patients with intermittent claudication (Rutherford 2-3) and critical limb ischemia (Rutherford 4-5)
  • Target lesion is located in the superficial femoral artery (minimal 1 cm from origin of SFA and minimal 1 cm above the edge of the patella)
  • Reference vessel diameter ≥4.5 and ≤6.5 mm (visual estimate)
  • Patients with a TASC A, B or C lesion
  • Diameter stenosis of target lesion >50% or chronic occlusions
  • Inflow arteries are free of hemodynamically significant obstruction (i.e. ≥50%)
  • The popliteal artery (outflow) is free of hemodynamically significant obstruction (i.e. ≥50%)
  • At least 1 patent below-the-knee vessel (anterior tibial artery, posterior tibial artery or peroneal artery) till the ankle confirmed by baseline angiography

Exclusion Criteria:

  • Patients with Rutherford 1 and 6
  • Patiens with Serum creatinine > 2.0 mg/dL or renal dialysis
  • Patient takes esomeprazole or omeprazole
  • Patient is pregnant
  • Patient suffers from acute limb ischemia defined as any sudden decrease in limb perfusion causing a potential threat to limb viability
  • Target lesion cannot be crossed with a guidewire
  • Target lesion is located in the popliteal artery
  • Patients with a nickel-titanium allergy
  • Patients with an aneurysm in the superficial femoral artery and popliteal artery
  • Patients with a TASC D lesion
  • Patients with a life expectancy <1 year
  • Patients with scheduled elective non-vascular procedures within 3 months after index-procedure, vascular procedures are allowed within 3 months after index-procedure if it is guaranteed that acetylic salicylic acid and clopidogrel intake is not interrupted
  • Patients with previous bypass surgery in the SFA
  • Patients with intolerance to antithrombotic medication (acetylic salicylic acid, clopidogrel, ticlopidine, glycoprotein IIb/IIIa inhibitors, direct thrombin inhibitors, etc)
  • Patient has not been premedicated with acetylic salicylic acid (at least 80 mg/day) 2 hours before the index-procedure
  • Patient has not been premedicated with clopidogrel (600 mg/day) 2 hours before the index-procedure
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01816854

Contacts
Contact: Jeroen Hendriks, MD, PhD +32 3 821 30 00 jeroen.hendriks@uza.be
Contact: Joris Coteur, MSc

Locations
Belgium
Antwerp University Hospital Recruiting
Antwerp, Belgium, 2650
Contact: Jeroen Hendriks, MD, PhD         
Sponsors and Collaborators
be Medical
Investigators
Principal Investigator: Jeroen Hendriks, MD, PhD University Hospital, Antwerp
  More Information

Responsible Party: be Medical
ClinicalTrials.gov Identifier: NCT01816854     History of Changes
Other Study ID Numbers: BM-HERO-07
Study First Received: March 20, 2013
Last Updated: July 15, 2015

Keywords provided by be Medical:
SFA,
stent,
endovascular
Patient outcome

Additional relevant MeSH terms:
Heart Diseases
Coronary Artery Disease
Myocardial Ischemia
Cardiovascular Diseases
Coronary Disease
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on September 21, 2017